Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

The show is over for Pulmocide’s phase 3 trial after patients who received its investigational inhaled antifungal had lower response rates and a higher number of deaths than those in the control arm.

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Important Readouts in 2026 for Phase 3 CTCL Study Soligenix, Inc. (NASDAQ:SNGX) is currently conducting the Phase 3 ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed the study, ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 ...